NF2/YAP信号通路通过FSP1诱导CD24高表达的三阴性乳腺癌细胞铁死亡  

NF2/YAP signaling pathway induces ferroptosis in triple negative breast cancer cells with high expression of CD24 by FSP1

作　　者：蒲卢兰 李静佳 陈宇 周瑜清 荣欣欣[1] 侯令密[2] 周方方 Pu Lulan;Li Jingjia;Chen Yu;Zhou Yuqing;Rong Xinxin;Hou Lingmi;Zhou Fangfang(School of Basic Medicine and Forensic Medicine,North Sichuan Medical College,Nanchong 637000,China;Department of Breast and Thyroid Surgery,Biological Targeting Laboratory of Breast Cancer,Affiliated Hospital of North Sichuan Medical College,Nanchong 637000,China)

机构地区：[1]川北医学院基础医学与法医学院,四川南充637000 [2]川北医学院附属医院甲状腺乳腺外科/乳腺癌生物靶向实验室,四川南充637000

出　　处：《中华乳腺病杂志（电子版）》2024年第4期206-211,共6页Chinese Journal of Breast Disease(Electronic Edition)

基　　金：四川省科技厅自然科学基金面上项目(2022NSFSC0775);四川省基层卫生事业发展研究中心资助项目(SWFZ22-C-82);南充市科技局市校科技战略合作项目(20SXQT0052);川北医学院校级科研发展计划项目(CBY22-QNA11)。

摘　　要：目的研究NF2和YAP表达对CD24高表达的三阴性乳腺癌细胞铁死亡的影响,探讨铁死亡的相关分子机制。方法培养CD24^(high)和CD24^(low)MDA-MB-231细胞,通过台盼蓝染色(TBA)实验检测经半胱氨酸饥饿、铁死亡诱导剂Erastin和RSL3处理后细胞的死亡情况,TBA法检测丙二醛(MDA)含量,分析细胞铁死亡水平。使用Western blot检测NF2和YAP在CD24^(high)和CD24^(low)MDA-MB-231细胞中的蛋白表达情况,并用慢病毒分别进行敲除和过表达,观察细胞铁死亡水平,并采用实时定量RT-PCR和Western blot检测成纤维细胞特异蛋白1(FSP1)的表达变化。结果经半胱氨酸饥饿、铁死亡诱导剂Erastin和RSL3分别处理后MDA-MB-231细胞死亡率增加,CD24^(low)细胞死亡率高于CD24^(high)细胞(t=14.548,P<0.001;t=8.310,P=0.001;t=8.600,P=0.001)。同时,TBA法结果显示,在含或不含半胱氨酸条件下,CD24^(high)和CD24^(low)MDA-MB-231细胞的MDA含量差异有统计学意义(t=-3.920,P=0.017;t=11.566,P<0.001);与对照组(DMSO)相比,CD24^(high)和CD24^(low)细胞经铁死亡诱导剂Erastin和RSL3处理后MDA水平增加,其中CD24^(low)细胞的MDA含量比CD24^(high)更高(t=10.763,P=0.006;t=24.067,P<0.001)。Western blot实验结果表明,NF2与YAP在CD24^(low)和CD24^(high)细胞的蛋白含量差异有统计学意义(t=-4.331,P=0.012;t=4.219,P=0.013),CD24^(low)细胞中YAP的蛋白表达更高(t=4.219,P=0.013),而CD24^(high)细胞中NF2的蛋白表达更高(t=-4.331,P=0.012)。在CD24^(high)MDA-MB-231细胞中构建NF2敲除或(和)YAP过表达细胞株,并用实时定量RT-PCR和Western blot检测,结果显示铁死亡关键蛋白FSP1在4组间的表达差异有统计学意义(F=30.297,P<0.001)。同时,检测NF2敲除或(和)YAP过表达后CD24^(high)MDA-MB-231细胞的铁死亡情况,结果表明敲除NF2或(和)过表达YAP后加入铁死亡诱导剂Erastin均可在一定程度上促进细胞死亡(F=38.911,P<0.050),其中在NF2敲除联合YAP过表达条件下,CD24^(high)MDA-MB-231细胞死亡率�Objective To observe the impact of NF2 and YAP expression on ferroptosis of triple negative breast cancer cells with high expression of CD24 and explore the related molecular mechanism.Methods MDA-MB-231 breast cancer cells with high expression of CD24(CD24^(high))and low expression of CD24(CD24^(low))were cultured.The cells were treated with ferroptosis agonists Erastin,RSL3 and cysteine starvation.The cell death was detected by Trypan blue staining(TBA).Malondialdehyde(MDA)content was measured using the TBA method to analyze the level of cellular ferroptosis.Western blot analysis was used to detect the protein expression of NF2 and YAP in CD24^(high)and CD24^(low)MDA-MB-231 cells.Lentiviral vectors were used to knock out and over-express NF2 and YAP,and changes in cellular ferroptosis were observed.The real-time quantitative RT-PCR and Western blot analysis were used to detect the expression of fibroblast-specific protein 1(FSP1)after NF2 knock out and YAP over-expression.Results After treatment with cysteine starvation,the ferroptosis inducers Erastin and RSL3,the death rate of MDA-MB-231 cells increased,with the death rate of CD24^(low)cells significantly higher than that of CD24^(high)cells(t=14.548,P<0.001;t=8.310,P=0.001;t=8.600,P=0.001).Meanwhile,the TBA method results showed that there was a significant difference in MDA content between CD24^(high)and CD24^(low)MDA-MB-231 cells under conditions with or without cysteine(t=-3.920,P=0.017;t=11.566,P<0.001);compared with the control group with DMSO,the MDA levels of CD24^(high)and CD24^(low)cells significantly increased after treatment with the ferroptosis inducers Erastin and RSL3,with the MDA content of CD24^(low)cells significantly higher than that of CD24^(high)cells(t=10.763,P=0.006;t=24.067,P<0.001).Western blot experiments showed that there was a significant difference in the protein content of NF2 and YAP between CD24^(low)and CD24^(high)MDA-MB-231 cells(t=-4.331,P=0.012;t=4.219,P=0.013),with higher expression of YAP protein in CD24^(low)cells(t=4.21

关 键 词：乳腺肿瘤 铁死亡 成纤维细胞特异蛋白1 NF2 YAP 

分 类 号：R737.9[医药卫生—肿瘤]